Holen Sie sich die Stockscreener-App
31.39
2.52%
-0.81
Handel nachbörslich:
31.39
Schlusskurs vom Vortag:
$32.20
Offen:
$32.09
24-Stunden-Volumen:
479.14K
Relative Volume:
0.82
Marktkapitalisierung:
$1.65B
Einnahmen:
$447.57M
Nettoeinkommen (Verlust:
$-38.92M
KGV:
-37.82
EPS:
-0.83
Netto-Cashflow:
$-1.15M
1W Leistung:
-2.73%
1M Leistung:
-7.68%
6M Leistung:
+3.26%
1J Leistung:
+40.20%
1-Tages-Spanne:
$30.85
$32.24
1-Wochen-Bereich:
$30.85
$33.15
52-Wochen-Spanne:
$20.20
$43.11
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Vergleichen Sie ATRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
31.39 | 1.65B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
540.60 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
177.27 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
89.30 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
255.88 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
221.22 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
Cryoablation Probe Market Size, Share | Industry Report 2030 - Grand View Research
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
Transcript : AtriCure, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
AtriCure at Goldman Sachs Conference: Strategic Growth Insights - Investing.com India
AtriCure at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Ameriprise Financial Inc. Invests $295,000 in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Global Cardiac Ablation Market: Advancements in Minimally Invasive Procedures and 13% CAGR by 2030 - PharmiWeb.com
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Jane Street Group LLC - Defense World
AtriCure (NASDAQ:ATRC) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
(ATRC) Investment Analysis - news.stocktradersdaily.com
AtriCure’s chief scientific officer sells $83,600 in stock By Investing.com - Investing.com India
Insider Sell: Vinayak Doraiswamy Sells 2,500 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure’s chief scientific officer sells $83,600 in stock - Investing.com Australia
Investors push AtriCure (NASDAQ:ATRC) 3.9% lower this week, company's increasing losses might be to blame - simplywall.st
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $823,000 Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure, Inc. (ATRC) Stock Analysis: Evaluating a 52.52% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Deutsche Bank AG - Defense World
AtriCure (NASDAQ:ATRC) Upgraded by Wall Street Zen to “Buy” Rating - Defense World
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | ATRC Stock News - GuruFocus
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Bank of America Corp DE Sells 208,694 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure Inc (ATRC) Trading 3.4% Higher on May 20 - GuruFocus
Focus Partners Wealth Acquires Shares of 16,306 AtriCure, Inc. (NASDAQ:ATRC) - Defense World
D. E. Shaw & Co. Inc. Sells 49,834 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
(ATRC) On The My Stocks Page - news.stocktradersdaily.com
AtriCure Stockholders Approve Stock Incentive Plan Amendment - TipRanks
Left Atrial Appendage Devices Market | Latest Trends, Growth, - openPR.com
AtriCure Names New COO, CFO - Medical Product Outsourcing
AtriCure Enrolls First Two Patients in DEEP Clinical Study - Medical Product Outsourcing
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect? - Yahoo Finance
Questex’s Fierce Healthcare Announces 2025 Fierce DEI Award Finalists - GlobeNewswire Inc.
When (ATRC) Moves Investors should Listen - news.stocktradersdaily.com
AtriCure Q1 2025 presentation: Revenue up 13.6%, raises full-year guidance - Investing.com
Dimensional Fund Advisors LP Purchases 136,015 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure CEO details growth trajectory toward becoming a $1B company - The Business Journals
AtriCure targets $517M-$527M revenue in 2025 with strong growth in appendage management and pain management - MSN
Left Atrial Appendage Closure Market to Set Phenomenal Growth - openPR.com
AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Call Transcript - Insider Monkey
Shareholders in AtriCure (NASDAQ:ATRC) have lost 40%, as stock drops 11% this past week - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch - simplywall.st
Needham cuts AtriCure stock target to $44, maintains buy rating By Investing.com - Investing.com Nigeria
AtriCure price target lowered to $52 from $58 at BTIG - TipRanks
AtriCure price target lowered to $51 from $52 at Canaccord - TipRanks
AtriCure’s Strong Q1: Revenue Growth and Challenges - TipRanks
Needham cuts AtriCure stock target to $44, maintains buy rating - Investing.com Australia
UBS Adjusts AtriCure (ATRC) Price Target Amid Core Business Stre - GuruFocus
AtriCure, Inc. SEC 10-Q Report - TradingView
UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating - marketscreener.com
14 Analysts Assess AtriCure: What You Need To Know - Benzinga
AtriCure (ATRC) Target Price Revised Amid Mixed Sector Performan - GuruFocus
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):